Compare Amgen, Inc. (AMGN) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Prudential PLC — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Prudential PLC trades at $28.36 (market cap $34.34B). The key difference: Amgen, Inc. is far larger — about 5.7× Prudential PLC's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | PUK | |
|---|---|---|
Market Cap | $196.12B | $34.34B |
Sector | Health | Financials |
52-Week High | $388.16 | $33.61 |
52-Week Low | $271.18 | $24.65 |
Enterprise Value | $241.41B | $35.78B |
Dividend Yield | 2.77% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Prudential Financial (PUK) trades at $28.13, up 1.33% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.16, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income reaching $2.29B. Analyst consensus is 50% buy, 37.5% hold, and 12.5% sell. Recent news highlights Q2 2026 earnings anticipation and strategic moves in India.
Outlook is positive with robust profitability and valuation appeal, but risks include Japan sales suspension and regulatory scrutiny. The stock offers growth potential from international expansion, supported by solid cash flow and equity performance. Investors should weigh near-term headwinds against long-term strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
